Taken together, these data support the combination of a PD-1 blocking antibody with a pro-inflammatory activation signal, such as poly(I:C), which may initiate an adaptive and innate immune-mediated anti-tumor response in CMS4 patients. Here, PDCD1 is linked to neoplasm.